COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial)

Slides:

Advertisements

Similar presentations

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.

Advertisements

Funding to Oxford University for MRC/BHF Heart Protection Study Medical Research Council$14M British Heart Foundation$2M Merck $8M Roche Vitamins$8M Designed,

ST Elevation Myocardial Infarction (STEMI)

The results of the Study of Heart and Renal Protection (SHARP)

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.

The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.

Valsartan Antihypertensive Long-Term Use Evaluation Results

Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.

The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.

Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.

British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,

OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.

Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.

Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.

Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients Daan Kromhout, MPH PhD for the Alpha Omega Trial Group.

Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Background Fibrinolytic Rx in STEMI is limited by inadequate reperfusion and/or reocclusion in ~25% of pts. An occluded infarct-related artery is associated.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.

CIBIS II Cardiac Insufficiency Bisoprolol Study

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.

RITA-3 ESC 4 th September 2005 The impact of underlying risk and gender on the benefit of early intervention in non-ST elevation acute coronary syndrome.

Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

Does early beta-blockade decrease mortality in STEMI?

ISIS-4: Fourth International Study of Infarct Survival Purpose To assess the separate and combined effects on all-cause mortality of adding early captopril,

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

4S: Scandinavian Simvastatin Survival Study

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.

JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

COMMIT/CCS-2 major efficacy results

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.

CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):

The Hypertension in the Very Elderly Trial (HYVET)

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Presentation transcript:

COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial) Designed, conducted, analysed and interpreted independently by COMMIT/CCS-2 collaboration Sources of funding (US$ 3M): SanofiAventis/BMS AstraZeneca British Heart Foundation UK Medical Research Council

COMMIT: Study design Mean treatment and follow-up: 16 days TREATMENT: Metoprolol 15 mg iv over 15 mins, then 200 mg oral daily vs matching placebo INCLUSION: Suspected acute MI (ST change or LBBB) within 24 h of symptom onset EXCLUSION: Shock, systolic BP <100 mmHg, heart rate <50/min or II/III AV block 1 OUTCOMES: Death & death, re-MI or VF/arrest up to 4 weeks in hospital (or prior discharge) Mean treatment and follow-up: 16 days

COMMIT: Baseline characteristics Characteristic Metoprolol Placebo (n=22,928) (n=22,923) Aged 70+ 26.1% 26.0% Time delay <6 h 34.0% 33.5% SBP <120 mmHg 33.7% 33.5% Anterior infarct 49.8% 49.6% Killip class II 20.0% 19.8% III 4.1% 4.2% Fibrinolytic given 49.8% 49.7%

COMMIT: Treatment compliance Compliance Metoprolol Placebo (n=22,927) (n=22,923) First iv dose given 98.5% 98.6% 3 iv doses completed 90.2% 96.0% Oral treatment completed 86.2% 91.6%

COMMIT: Effects of METOPROLOL on Reinfarction Outcome Metoprolol Placebo Odds ratio & 95% CI after Re-MI (22,927) (22,922) Metop. better Placebo better Died 206 (0.9%) 226 (1.0%) Survived 261 (1.1%) 342 (1.5%) 18% SE 6 ALL COMBINED 467 (2.0%) 568 (2.5%) (2P = 0.002) 0.4 0.7 1.0 1.3 1.6 1.9

Effects of iv then oral -blocker on reinfarction in 3 major trials of acute MI Trial ß-blocker Control Odds ratio & 95% CI (33,841) (33,813) ß-blocker better Control better MIAMI 85 (3.0%) 111 (3.8%) ISIS-1 148 (1.8%) 161 (2.0%) COMMIT 467 (2.0%) 568 (2.5%) 17% SE 5 OVERALL 700 (2.1%) 840 (2.5%) (2P = 0.0003) 0.4 0.6 0.8 1.0 1.2 1.4 1.6

COMMIT: Effects of METOPROLOL on Cardiac Arrest Events Metoprolol Placebo Odds ratio & 95% CI (22,927) (22,922) Metop. better Placebo better VF 582 (2.5%) 699 (3.0%) 17% SE 5 Other arrest 882 (3.8%) 899 (3.9%) 2% SE 5 5% SE 4 ANY OF ABOVE 1267 (5.5%) 1332 (5.8%) (2P > 0.1; NS) 0.4 0.7 1.0 1.3 1.6 1.9

COMMIT: Effects of METOPROLOL on Death in hospital Placebo: 1798 deaths (7.8%) Metoprolol: 1776 deaths (7.7%) 1% (SE 3) relative risk reduction (2P=0.7) % dead Days since randomisation

COMMIT: Effects of METOPROLOL on Death by attributed cause(s) Placebo Odds ratio & 95% CI (22,927) (22,922) Metop. better Placebo better Arrhythmia 388 (1.7%) 498 (2.2%) 22% SE 6 Shock 496 (2.2%) 384 (1.7%) -29% SE 8 Other causes 892 (3.9%) 916 (4.0%) 3% SE 5 1% SE 3 ANY DEATH 1776 (7.7%) 1798 (7.8%) (2P > 0.1; NS) 0.4 0.7 1.0 1.3 1.6 1.9

COMMIT: Effects of METOPROLOL on Cardiogenic Shock by day of event Placebo Odds ratio & 95% CI (22,927) (22,922) Metop. better Placebo better 475 (2.1%) 317 (1.4%) 1 282 (1.2%) 210 (0.9%) 2+ 384 (1.7%) 361 (1.6%) -29% SE 5 ALL 1141 (5.0%) 888 (3.9%) (2P < 0.00001) 0.4 0.7 1.0 1.3 1.6 1.9

COMMIT: Effects of METOPROLOL on Cardiogenic Shock by Killip class Baseline Metoprolol Placebo Odds ratio & 95% CI Killip class (22,927) (22,922) Metop. better Placebo better I 611 (3.5%) 487 (2.8%) II 362 (7.9%) 296 (6.5%) III 155 (16.2%) 100 (10.4%) -29% SE 5 ALL 1141 (5.0%) 888 (3.9%) (2P < 0.00001) 0.4 0.7 1.0 1.3 1.6 1.9

COMMIT: Absolute effects of METOPROLOL on Re-MI, VF, Shock and Death by KILLIP class at entry Absolute differences per 1000 Re-MI VF Shock Death I 4 3 -7 II 10 11 -14 III -5 -58 -36 Any 5 -11 1

COMMIT: Effects of METOPROLOL on Death, Re-MI or Arrest by prognosis & fibrinolytic Baseline Metoprolol Placebo Odds ratio & 95% CI features (22,927) (22,922) Metop. better Placebo better Prognostic index Good 248 (3.3%) 284 (3.7%) Average 575 (7.5%) 642 (8.4%) Poor 1350 (17.6%) 1338 (17.5%) Lytic given Yes 1031 (9.0%) 1137 (10.0%) No 1142 (9.9%) 1127 (9.8%) 4% SE 3 ALL 2173 (9.5%) 2264 (9.9%) (2P > 0.1; NS) 0.4 0.6 0.8 1.0 1.2 1.4 1.6

COMMIT: Effects of METOPROLOL on Death by shock index Placebo Odds ratio & 95% CI index (22,927) (22,922) Metop. better Placebo better Good 654 (4.1%) 719 (4.5%) Average 569 (12.1%) 598 (12.6%) Poor 553 (25.9%) 481 (23.4%) 1% SE 3 ALL 1776 (7.7%) 1798 (7.8%) (2P > 0.1; NS) 0.4 0.7 1.0 1.3 1.6

COMMIT: Conclusions Slides available on: www.commit-ccs2.org  Metoprolol (15 mg iv, then 200 mg oral daily) in acute MI did not significantly reduce mortality in hospital  It reduced the absolute risks of reinfarction by 5 per 1000 (P=0.001) and of VF by 5 per 1000 (P<0.001)  But, overall, it increased the risk of cardiogenic shock by 11 per 1000 (P<0.00001), chiefly on days 0-1  In acute MI, it may be better to start beta-blocker when the patient is stable (and then continue long-term) Slides available on: www.commit-ccs2.org